Evidence map›Paper›PMID 39516493›Full record

ArticleScientific reports2024

Auxiliary effect of trolox on coenzyme Q

Shikha Upreti, Prachi Sharma, Seema Sen, Subhrajit Biswas, Madhumita P Ghosh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Optimized CoQ10 deliveryRSC advances · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shikha UpretiOcular Pharmacology and Therapeutics Lab, Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, 201313, India.ORCID http://orcid.org/0000-0002-5180-6712
Prachi SharmaAmity Institute of Molecular Stem Cell and Cancer Research, Amity University Uttar Pradesh, Noida, 201313, India.ORCID http://orcid.org/0000-0002-0162-9906
Seema SenDepartment of Ocular Pathology, Dr R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.ORCID http://orcid.org/0000-0001-9649-9616
Subhrajit BiswasAmity Institute of Molecular Stem Cell and Cancer Research, Amity University Uttar Pradesh, Noida, 201313, India.ORCID http://orcid.org/0000-0001-5649-364X
Madhumita P GhoshOcular Pharmacology and Therapeutics Lab, Centre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, 201313, India. mpghosh@amity.edu.ORCID http://orcid.org/0000-0002-3272-6821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive oxygen species (ROS) are essential for cancer signalling pathways and tumour maintenance, making ROS targeting a promising anti-cancer strategy. Coenzyme Q

Indexed as

ApoptosisCell ProliferationChromansNeovascularization, PathologicProto-Oncogene Proteins c-aktReactive Oxygen SpeciesRetinoblastomaUbiquinoneAngiogenesisAnimalsAntioxidantsCell Line, TumorCell SurvivalChick EmbryoHumansHuman Umbilical Vein Endothelial Cells6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acidAntioxidantsChromanscoenzyme Q10Proto-Oncogene Proteins c-aktReactive Oxygen SpeciesUbiquinoneAnti-cancerCoQ10ERK/Akt inhibitionRb cellsTrolox

Identifiers

PMID39516493
PMCPMC11549309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.